000			04051nam a22004575i 4500
001			298519
003			MX-SnUAN
005			20160429155508.0
007			cr nn 008mamaa
008			150903s2009 gw | o |||| 0|eng d
020			_a9783540857938 _99783540857938
024	7		_a10.1007/9783540857938 _2doi
035			_avtls000352124
039		9	_a201509030934 _bVLOAD _c201405060301 _dVLOAD _y201402171153 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRM1-950
100	1		_aRehbinder, Eckard. _eautor _9334955
245	1	0	_aPharming : _bPromises and risks of biopharmaceuticals derived from genetically modified plants and animals / _cby Eckard Rehbinder, E. Rehbinder, M. Engelhard, K. Hagen, R. B. Jørgensen, R. Pardo-Avellaneda, A. Schnieke, F. Thiele.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2009.
300			_brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aEthics of Science and Technology Assessment, Schriftenreihe der Europäischen Akademie zur Erforschung von Folgen wissenschaftlich-technischer Entwicklungen Bad Neuenahr-Ahrweiler GmbH, _x1860-4803 ; _v35
500			_aSpringer eBooks
505	0		_aThe technology of pharming -- Risk assessment of plant pharming and animal pharming -- The welfare of pharming animals -- Public views and attitudes to pharming -- The ethical evaluation of pharming -- The role of patents in the development of pharming -- Legal problems of pharming -- Conclusions and recommendations.
520			_aRecent scientific advances have made it possible to produce biopharmaceuticals in genetically modified plants and animals, such as maize, tobacco, goats, and chickens. This new branch of biotechnology is termed pharming, composed of the terms pharmaceuticals and farming. Pharming constitutes an overlap of red and green biotechnology. It offers the prospect of a quicker, cheaper, and more flexible production of biopharmaceuticals compared with current production processes. This is a promising perspective in light of the rapidly growing market of biopharmaceuticals, although the economic competitiveness of pharming remains to be proven. Besides possible benefits for producers, patients and health care systems, pharming also raises a number of complex ecological, social, moral and legal questions that have as yet not been thoroughly discussed. The present book contains the findings of an interdisciplinary research project that has addressed a large range of questions associated with pharming: An analysis of the state-of-the-art of plant pharming and animal pharming technologies is followed by an assessment of environmental risks related to pharming and welfare risks for pharming animals. Public views and attitudes to pharming are investigated on the basis of a comprehensive survey in 15 countries. Moreover, ethical and legal questions, posed by present and foreseeable future practices of pharming, are analysed. The concluding chapter presents the authors’ main findings and recommendations, addressed to science, industry, politics and general public interested in the chances and risks of this upcoming field of biotechnology.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aRehbinder, E. _eautor _9334956
700	1		_aEngelhard, M. _eautor _9334957
700	1		_aHagen, K. _eautor _9334958
700	1		_aJørgensen, R. B. _eautor _9334959
700	1		_aPardo-Avellaneda, R. _eautor _9334960
700	1		_aSchnieke, A. _eautor _9334961
700	1		_aThiele, F. _eautor _9334962
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9783540857921
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-540-85793-8 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c298519 _d298519